Paratek Pharmaceuticals’ stock price has risen by 20% following reports from Betaville Intelligence that a private equity firm is a leading suitor for a takeover. Paratek markets the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline). Although Seeking Alpha’s Quant Rating views Paratek as a hold, it is important to note that such reports are often based on rumors and speculation, and there is no guarantee that any takeover will actually take place.
- Paratek Pharmaceuticals (NASDAQ:PRTK) is up 20% in Tuesday afternoon trading amid a report that the biopharma is a takeout target.
- Betaville Intelligence is reporting that those familiar with the situation say a private equity firm is the leading suitor.
- Paratek’s (PRTK) marketed products include the antibiotics Nuzyra (omadacycline) and Seysara (sarecycline).
- Seeking Alpha’s Quant Rating views Paratek (PRTK) as a hold.
Source: SeekingAlpha
